NIPPON KAYAKU Aktie

 

Partnership supports development of tumor-activated glycan-directed ADC designed to improve tumor selectivity NEW TAIPEI CITY, Taiwan, March 23, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of......

Das Instrument NP7 JP3694400007 NIPPON KAYAKU EQUITY wird cum Dividende/Zinsen gehandelt am 27.03.2025 und ex Dividende/Zinsen am 28.03.2025 The instrument NP7 JP3694400007 NIPPON KAYAKU EQUITY has its pre-dividend/interest day on 27.03.2025 and its ex-dividend/interest day on 28.03.2025...

U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC); Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Innovent Biologics' commercialization of taletrectinib underway in China after recent line agnostic approval for advanced ROS1+ NSCLC; Nippon Kayaku completed submission of a Marketing Authorization Application (MAA) for taletrectinib in Japan for the same indication Launched an Expanded Access Program (EAP) in the U.S. for taletrectinib for advanced ROS1+ NSCLC in February 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $502.7 million as of December 31, 2024 Secured up to $250 million in non-dilutive financings from Sagard Healthcare Partners in March 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, toda...